Glaxo's asthma drug approved: The pharmaceutical giant has received a badly needed boost, reports Gail Counsell
Tuesday 09 March 1993
The drug, fluticasone propionate, is already available as a treatment for hay fever under the name Flixonase. But its extension to the pounds 2.5bn-a-year respiratory market is important for Glaxo, which badly needs to broaden its product base.
More than half of Glaxo's profits are currently dependent on one drug, Zantac, the anti-ulcer treatment, and the performance of some of its newer drugs has proved disappointing.
The news boosted Glaxo's share price, which went on a roller- coaster ride yesterday following weekend reports that America's Food and Drug Administration had criticised the marketing of Zantac. In heavy trading, its shares tumbled 28p but recovered to close down 8p at 652p.
Glaxo, under its chief executive, Ernest Mario, played down the reports, admitting that the FDA had written in January warning that in its view some of the promotional claims made for Zantac were not justified.
But Glaxo insisted that the 'safety and effectiveness' of Zantac had not been called into question, and pointed out that at most the FDA would require it to write to US physicians correcting certain of the claims it had made.
Analysts said the problem was commonly encountered by drug companies. 'It's a storm in a teacup,' Paul Woodhouse, an analyst with Smith New Court, said.
The Stock Exchange said that it would be looking as a matter of routine at the movement in the share price. The implication is that a statement should perhaps have been made by the company when the problem arose.
But Mr Woodhouse insisted that the issue had been well aired. 'This was raised and discussed with analysts following the interim results last month,' he said.
Flixotide is an improved version of an inhaled steroid, a type of drug increasingly used to treat asthma since it attacks the inflammation that causes the asthma. Conventional treatments such as Glaxo's best-selling Ventolin merely ease its symptoms. Flixotide will therefore be able to substitute for lost Ventolin sales. It is also held to be more powerful and to have fewer side-effects than other steroids on the market.
(Photograph and graph omitted)
- 1 Christmas comes early to Hong Kong, as millions of bank notes spill out onto busy street
- 2 The 'Black Museum': After 150 years, public can visit police’s grisly crime museum
- 4 Vagina canoe artist facing two years in jail defends herself over ‘obscenity’ charges
- 5 The Queen’s speech 2014: Recap and Twitter reaction to Game of Thrones reference
PlayStation and Xbox hacked by Lizard Squad
Antonio Martin shooting: Black teenager may have tried to ambush patrolman, says police officer's lawyer
Katie Hopkins speaks out on childhood obesity: 'Parents of fat children should be prosecuted for child cruelty'
Boxing Day snowfall could push even more bargain-hunters online for Christmas sales
The 'Black Museum': After 150 years, public can visit police’s grisly crime museum
British actor Idris Elba cannot star as James Bond because he is black, says shock jock Rush Limbaugh
Rozanne Duncan: Ukip expels councillor for 'jaw-dropping' comments made in BBC TV interview
Germany anti-Islam protests: 17,000 march on Dresden against 'Islamification of the West'
Ukip member gets into Christmas spirit with Union Flag plea to Santa 'for our country back'
BBC director Danny Cohen: Rising UK antisemitism makes me feel more uncomfortable than ever
Alex Salmond has 'broken his word to the Scottish people' says Scottish Lib Dem leader
iJobs Money & Business
Highly Competitive: Selby Jennings: Our client, a leading European Oil trading...
£43500 per annum + pension + holidays: The Jenrick Group: Night Shift Operatio...
£20000 - £25000 per annum + OTE £40,000 + Car + Pension: SThree: SThree are a ...
£20000 - £25000 per annum + OTE £35K: SThree: We consistently strive to be the...